 Dianna Quan
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polyneuropathies | 9 | 2025 | 57 | 1.960 |
Why?
| | Amyloid Neuropathies, Familial | 6 | 2025 | 26 | 1.650 |
Why?
| | Muscular Atrophy, Spinal | 2 | 2021 | 24 | 1.160 |
Why?
| | Prealbumin | 5 | 2025 | 37 | 0.960 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2021 | 96 | 0.860 |
Why?
| | Motor Neuron Disease | 2 | 2021 | 20 | 0.750 |
Why?
| | Neural Conduction | 4 | 2018 | 92 | 0.700 |
Why?
| | Point Mutation | 2 | 2016 | 241 | 0.620 |
Why?
| | Muscle Weakness | 4 | 2018 | 92 | 0.580 |
Why?
| | Muscle, Skeletal | 3 | 2019 | 1791 | 0.580 |
Why?
| | Myositis | 1 | 2019 | 57 | 0.560 |
Why?
| | Electromyography | 5 | 2021 | 419 | 0.480 |
Why?
| | Neuromuscular Diseases | 2 | 2008 | 145 | 0.480 |
Why?
| | TRPV Cation Channels | 1 | 2016 | 43 | 0.480 |
Why?
| | RNA, Small Interfering | 4 | 2025 | 638 | 0.460 |
Why?
| | Biopsy | 1 | 2019 | 1082 | 0.450 |
Why?
| | Critical Illness | 3 | 2018 | 900 | 0.420 |
Why?
| | Polymyositis | 1 | 2011 | 13 | 0.340 |
Why?
| | Muscular Dystrophies | 1 | 2011 | 28 | 0.330 |
Why?
| | Pain | 1 | 2016 | 791 | 0.330 |
Why?
| | Electrodiagnosis | 2 | 2012 | 17 | 0.310 |
Why?
| | Multiple Sclerosis | 2 | 2005 | 489 | 0.300 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 41 | 0.280 |
Why?
| | Intensive Care Units | 6 | 2018 | 924 | 0.270 |
Why?
| | Nervous System Diseases | 1 | 2011 | 286 | 0.270 |
Why?
| | Diagnostic Errors | 1 | 2008 | 178 | 0.250 |
Why?
| | Diagnosis, Differential | 4 | 2016 | 1512 | 0.240 |
Why?
| | Antibodies | 1 | 2008 | 397 | 0.240 |
Why?
| | Patient Discharge | 3 | 2018 | 995 | 0.240 |
Why?
| | Neuralgia, Postherpetic | 1 | 2006 | 40 | 0.230 |
Why?
| | Valine | 1 | 2006 | 83 | 0.230 |
Why?
| | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2005 | 5 | 0.230 |
Why?
| | Acyclovir | 1 | 2006 | 98 | 0.230 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 29 | 0.220 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 44 | 0.220 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 134 | 0.200 |
Why?
| | Neuralgia | 2 | 2021 | 140 | 0.200 |
Why?
| | Myasthenia Gravis | 1 | 2023 | 24 | 0.200 |
Why?
| | Activities of Daily Living | 2 | 2023 | 444 | 0.180 |
Why?
| | Humans | 29 | 2025 | 145785 | 0.180 |
Why?
| | Ketamine | 1 | 2003 | 137 | 0.170 |
Why?
| | Aged | 12 | 2025 | 26217 | 0.170 |
Why?
| | Duloxetine Hydrochloride | 1 | 2021 | 10 | 0.170 |
Why?
| | Nortriptyline | 1 | 2021 | 9 | 0.170 |
Why?
| | Sural Nerve | 2 | 2014 | 22 | 0.160 |
Why?
| | Antiviral Agents | 1 | 2006 | 769 | 0.160 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 38 | 0.150 |
Why?
| | Herpes Zoster | 1 | 2003 | 319 | 0.150 |
Why?
| | Adult | 13 | 2025 | 40882 | 0.150 |
Why?
| | Middle Aged | 14 | 2025 | 36309 | 0.140 |
Why?
| | Motor Neurons | 1 | 2021 | 236 | 0.140 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8347 | 0.140 |
Why?
| | Analgesics | 1 | 2021 | 231 | 0.140 |
Why?
| | Female | 19 | 2025 | 79045 | 0.140 |
Why?
| | Male | 18 | 2025 | 73012 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 261 | 0.140 |
Why?
| | Muscle Strength | 2 | 2020 | 332 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2181 | 0.130 |
Why?
| | Quality of Life | 4 | 2025 | 3211 | 0.120 |
Why?
| | Pain Management | 1 | 2021 | 411 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2025 | 11794 | 0.120 |
Why?
| | Prospective Studies | 5 | 2025 | 8078 | 0.120 |
Why?
| | Rhabdomyolysis | 1 | 2015 | 24 | 0.110 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 130 | 0.110 |
Why?
| | Physical Exertion | 1 | 2015 | 205 | 0.100 |
Why?
| | Peroneal Nerve | 1 | 2014 | 18 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 2000 | 0.100 |
Why?
| | Neurologic Examination | 1 | 2014 | 132 | 0.100 |
Why?
| | Electrophysiology | 1 | 2014 | 218 | 0.100 |
Why?
| | Muscular Diseases | 2 | 2017 | 109 | 0.100 |
Why?
| | Bed Rest | 1 | 2012 | 14 | 0.090 |
Why?
| | Immunoglobulins | 2 | 2009 | 163 | 0.080 |
Why?
| | Biomarkers | 1 | 2022 | 4302 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2025 | 17330 | 0.080 |
Why?
| | Phenotype | 2 | 2016 | 3170 | 0.080 |
Why?
| | Physical Examination | 1 | 2011 | 244 | 0.080 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1505 | 0.070 |
Why?
| | Meningoencephalitis | 1 | 2009 | 24 | 0.070 |
Why?
| | West Nile Fever | 1 | 2009 | 57 | 0.070 |
Why?
| | Frontal Lobe | 1 | 2010 | 160 | 0.070 |
Why?
| | Physical Therapy Modalities | 1 | 2012 | 337 | 0.070 |
Why?
| | Electrodes | 1 | 2008 | 111 | 0.070 |
Why?
| | Immunocompromised Host | 1 | 2009 | 202 | 0.070 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2010 | 533 | 0.070 |
Why?
| | Sepsis | 1 | 2014 | 664 | 0.060 |
Why?
| | Respiration, Artificial | 3 | 2018 | 714 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2009 | 260 | 0.060 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2007 | 27 | 0.060 |
Why?
| | Injections, Intravenous | 1 | 2006 | 197 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2009 | 332 | 0.060 |
Why?
| | Peripheral Nervous System | 1 | 2005 | 20 | 0.060 |
Why?
| | Guillain-Barre Syndrome | 1 | 2005 | 23 | 0.060 |
Why?
| | Cranial Nerves | 1 | 2005 | 12 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 544 | 0.060 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2005 | 47 | 0.060 |
Why?
| | Action Potentials | 1 | 2008 | 502 | 0.060 |
Why?
| | Graves Disease | 1 | 2005 | 32 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2020 | 2064 | 0.050 |
Why?
| | Young Adult | 2 | 2019 | 14254 | 0.050 |
Why?
| | Hypertrophy | 1 | 2005 | 128 | 0.050 |
Why?
| | Executive Function | 1 | 2010 | 470 | 0.050 |
Why?
| | Neuropsychological Tests | 1 | 2010 | 1137 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2008 | 592 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 740 | 0.050 |
Why?
| | Friedreich Ataxia | 1 | 2005 | 78 | 0.050 |
Why?
| | Treatment Failure | 1 | 2005 | 360 | 0.050 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2007 | 356 | 0.050 |
Why?
| | Adolescent | 3 | 2019 | 22577 | 0.050 |
Why?
| | Axons | 1 | 2005 | 204 | 0.050 |
Why?
| | Administration, Oral | 1 | 2006 | 867 | 0.050 |
Why?
| | Drug Evaluation | 1 | 2003 | 79 | 0.050 |
Why?
| | Exercise | 1 | 2015 | 2205 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2005 | 166 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 1043 | 0.050 |
Why?
| | Central Nervous System | 1 | 2005 | 282 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2003 | 127 | 0.050 |
Why?
| | Gels | 1 | 2003 | 85 | 0.050 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2002 | 29 | 0.050 |
Why?
| | Patients | 1 | 2023 | 183 | 0.040 |
Why?
| | Colorado | 2 | 2024 | 4556 | 0.040 |
Why?
| | Genetic Testing | 1 | 2024 | 483 | 0.040 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2003 | 128 | 0.040 |
Why?
| | North America | 1 | 2002 | 304 | 0.040 |
Why?
| | Mexiletine | 1 | 2021 | 6 | 0.040 |
Why?
| | Pregabalin | 1 | 2021 | 12 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 838 | 0.040 |
Why?
| | RNAi Therapeutics | 1 | 2019 | 7 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2021 | 169 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 977 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 428 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 421 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2933 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Prevalence | 1 | 2024 | 2875 | 0.030 |
Why?
| | APACHE | 1 | 2016 | 68 | 0.030 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 59 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1509 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 377 | 0.030 |
Why?
| | Creatine Kinase | 1 | 2015 | 72 | 0.030 |
Why?
| | Ultrasonography | 1 | 2018 | 788 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2017 | 1038 | 0.020 |
Why?
| | Brain | 1 | 2005 | 2969 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2005 | 3916 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2139 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 2012 | 37 | 0.020 |
Why?
| | Patient Readmission | 1 | 2017 | 773 | 0.020 |
Why?
| | Length of Stay | 1 | 2017 | 1350 | 0.020 |
Why?
| | Mobility Limitation | 1 | 2012 | 67 | 0.020 |
Why?
| | Muscular Atrophy | 1 | 2012 | 87 | 0.020 |
Why?
| | Muscle Fatigue | 1 | 2012 | 98 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2123 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2012 | 311 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 95 | 0.020 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2009 | 61 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 305 | 0.020 |
Why?
| | Child | 1 | 2008 | 22740 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 210 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 6033 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2007 | 32 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7134 | 0.020 |
Why?
| | Graft Rejection | 1 | 2009 | 521 | 0.010 |
Why?
| | Pedigree | 1 | 2007 | 515 | 0.010 |
Why?
| | Pilot Projects | 1 | 2010 | 1898 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2009 | 872 | 0.010 |
Why?
| | Algorithms | 1 | 2012 | 1851 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 4330 | 0.010 |
Why?
| | Disease Progression | 1 | 2009 | 2865 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 4090 | 0.010 |
Why?
| | Infant | 1 | 2007 | 10091 | 0.010 |
Why?
|
|
Quan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|